CN1188646A - Preparation of concealed taste preparations of antibucterially active quinlone derivatives - Google Patents
Preparation of concealed taste preparations of antibucterially active quinlone derivatives Download PDFInfo
- Publication number
- CN1188646A CN1188646A CN98104286A CN98104286A CN1188646A CN 1188646 A CN1188646 A CN 1188646A CN 98104286 A CN98104286 A CN 98104286A CN 98104286 A CN98104286 A CN 98104286A CN 1188646 A CN1188646 A CN 1188646A
- Authority
- CN
- China
- Prior art keywords
- described methods
- preparation
- quinolone derivative
- antibacterial activity
- taste
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a preparation method of anti-bacterial activity quinolone derivative oral medicinal preparation with the covered smell and a preparation prepared by the method.
Description
The present invention relates to prepare the method for having covered quinolone derivative oral drug preparation taste, that have antibacterial activity.
That the antibacterial activity inhibitor of known quinolione class directed toward bacteria gyrase has is intrinsic, extremely bitter taste.When taking the oral formulations of this type of material, must cover this intrinsic bitterness so that patient is easy to accept.With regard to rule,, finishes in tablet by being carried out the film coating.When treating with the quinolone derivative of antibacterial activity, needing single dose is the medicine of 100mg to 1000mg.Swallow the big like this solid pharmaceutical dosage formulation of volume to the old people with swallow inconvenient patient and child and have very big difficulty, so need oral Pharmaceutical dosage forms, its taste can be accepted, and do not need whole solid dosage forms is swallowed together, but can take or take in liquid suspension by chewing.
The simplest technological means of covering undesirable taste is to add suitable correctives in the solution of medicine.For the quinolone derivative of antibacterial activity, this but is unfavorable.Therefore, need the additional step this bitterness of covering or neutralize.
Present known technology is intended to prevent or is to reduce the quinolone derivative of easily molten antibacterial activity at solvent for use or the dissolubility in saliva at least.
In EP-A-0551820, by achieving the above object with the dehydrate microencapsulation of these material base forms.As coating substance, use water-soluble neutral methyl ester and/or the ethyl ester compound or the quarternary ammonium salt compound of polymethylacrylic acid, or its mixture, perhaps ethyl cellulose.
The bio-pharmaceutical communique, (1993), 16 (2), described among the 172-7 and used low ethyl cellulose that replaces and hydroxypropyl methylcellulose as coating substance, the fine grained of Sparfloxacin and hydroxypropyl cellulose is carried out the method for microencapsulation.
EP-A-409254 has described similar methods, promptly uses the mixture of ethyl cellulose and water-soluble polymer that pyridone carboxylic acid antibacterial (particularly enoxacin) and water-soluble bloated reagent are carried out microencapsulation.
In the method for these microencapsulation, coating substance is by applying with its solution spray.Its shortcoming is to need expensive mounting equipment and to by strictness of the implemented restriction of the applicable graininess of coated granule.This is because the requirement that the reduction of granularity has brought beyong contemplation on the one hand, and the reduction of granularity causes fusible increase on the other hand, causes the increasing of agglomeration tendency, thereby has limited the probability of spray coating technically.
Therefore, mention among the EP-A-0551820 that 100-500 μ m is the preferred size scope of gained microcapsule.But 500 μ m granules are given in the disease population surely and can be caused offending sand feeling as suspensoid.In addition, the time of spray coating fine grained needs is longer.
JP63150220 has described the method that can obtain being similar to the microcapsule product.Powdery medicine such as enoxacin and Powdered coating substance such as wax material such as paraffin, stearic acid, Cera Flava etc. or mix with the polymer that can form the film coating such as methacrylic acid copolymer, ethyl cellulose, polystyrene etc.Handle this mixture with organic solvent, thereby coating substance is dissolved.Except that after desolvating, the powdered substance of getting back.The shortcoming of this method be used solvent inflammable, be harmful to health or bring ecological problem.These solvents must reclaim or handle by expensive method.Remaining in addition in product.
As dissolving or disperse the medium of coating substance, in all methods of the coating of the quinolone derivative of existing, active ingredient composition granule or antibacterial activity, is common with liquid-carrier.
The purpose of this invention is to provide preparation method can be oral, the concealed pharmaceutical preparation of taste, wherein but rapid release is as the quinolone derivative of the antibacterial activity of reactive compound, the shortcoming that does not exist the method in the document to describe, and avoided using the medium of liquid-carrier as dissolving or dispersion coating substance.
The rapid release of active substance is meant that in 900ml 0.1N HCl the release of single dose is at least 80% after 30 minutes.
Surprisingly, have now found that, even also can taste masking without liquid-carrier.Its method is, with the quinolone derivative of antibacterial activity and higher fatty acids and, in case of necessity, other additive mixes, and with mixture heated, after the cooling, makes powder or granule.Even after pulverizing, this product still can suitably be covered taste.The heating of mixture can be carried out according to conventional method.Consider from the angle of treatment process, preferably used the heating mixer (as Henschel liquid mixer FM4 or FM10) of high speed rotating.In these blenders,,, in uniform machinery, can after cooling, mixture be pulverized mixture heated by frictional heat.High speed rotating refers to that rotating speed is at least 3000rpm.With mixture heated to 30 ℃ to 140 ℃, preferred 40 ℃ to 120 ℃, preferred especially 50 ℃ to 85 ℃.
The invention still further relates to preparation by the method preparation.
Higher fatty acids refers to contain the fatty acid of at least 10 carbon atoms.
Suitable higher fatty acids has 10 to 22 carbon atoms, and the fatty acid with 12 to 18 carbon atoms is to described method particularly suitable.Also can preferably use fatty acid mixt.For example, using commercially available stearic acid is easily, and this stearic acid is the stearic acid of almost equivalent and the mixture of Palmic acid.Suitable additive also has for example Silicon stone of high dispersive.
As basic architectural characteristic, the quinolone derivative of antibacterial activity contains 1-ethyl-4-oxo pyridine-3-carboxylic acid (seeing Auterhoff, Knabe, Holtje, (" pharmaceutical chemistry textbook ", the 13rd edition, 1994,788 pages)).Preferred levofloxacin (levofloxacin), ofloxacin, ciprofloxacin, Flucloxacillin, Sparfloxacin and enoxacin.More preferably levofloxacin, ofloxacin.
Quinolone derivative (one or more) is preferably 1: 0.3 to 1: 4, preferred especially 1: 1 to 1: 2 with the weight ratio of fatty acid (one or more).
According to the present invention through heating and subsequently the antimicrobial chemical quinolone derivative of pulverization process and the preparation of higher fatty acids can further make medicine, as make sachet, chewable tablet or soluble tablet.
1. soluble tablet
Soluble tablet is a kind of pharmaceutical dosage form, when in one glass of water, stirring, and disintegrate and form suspensoid in maximum 3 minutes, this suspensoid can be by the screen cloth of 0.715mm.
Soluble tablet needs heavy dose of administration as medicament.Because of its volume is big, be difficult to swallow as conventional tablet.Soluble tablet special administering mode in suspension or solution need suitably be covered the bad taste of medicine.
Can prepare the soluble tablet agent with the used adjuvant of conventional tablet.In general, also can add correctives, sweeting agent and possible coloring agent.The technology of preparing of using is wet granulation, dry granulation and direct compression.
2. sachet
Sachet is the bag that the Powdered or granular medicament of a single dose is housed usually.During administration, with the medicine suspendible in the bag or be dissolved in one glass of water.Except that sugar and sugar replacement, suitable additive is thickening agent, fluidizer, correctives, coloring agent and possible buffer substance.
3. chewable tablet
Chewable tablet is the tablet of chewing earlier before swallowing.Concerning the quinolone derivative of the antibacterial activity of heavy dose, the reason of using this pharmaceutical dosage form is the swallow problems of some patients to conventional tablet, film-coated tablet, capsule or coated tablet.Except that the conventional tablet adjuvant, chewable tablet mainly contains the substitute and the correctives of sugar or sugar usually.
Being released in the blade mixer in the American Pharmacopeia of active substance measured, and sees 23,1792 pages of American Pharmacopeias, 711 joints, Fig. 2.
EXAMPLE Example 1
The preparation taste is concealed, the preparation of the basic mixture of levofloxacin semihydrate.
Levofloxacin semihydrate 256.23mg
Stearic acid 211.00mg
The levofloxacin semihydrate was mixed in the heating mixer of rotating speed 1000rpm 3 minutes with stearic acid.Then rotating speed is increased to 5500rpm, and is mixed to temperature and is increased to 75 ℃, this material is grain structure.With overcoat cooling this mixture is cooled to room temperature, then by at 4 * 0.5 minutes the inherent refrigerative while with 5500rpm further mixing pulverize.Obtain the powder of taste nature.
In the American Pharmacopeia blade mixer, measure the release of this active mixture, obtain following result:
Release medium
900ml water 900ml 0.1N HCl
After 5 minutes 34.2% 91.2%
After 15 minutes 47.1% 97.9%
55.7% 97.4% embodiment 2 after 30 minutes
Further handle the mixture of the embodiment 1 of taste masking, obtain soluble tablet.
The levofloxacin semihydrate/
Stearic acid mixture 467.23mg
Corn starch 243.77mg
Microcrystalline Cellulose 200.00mg
Micronized polyvinylpolypyrrolidone 50.00mg
Polyvinylpyrrolidone 5.00mg
Levofloxacin semihydrate/stearic acid mixture, corn starch, microcrystalline Cellulose, micronize polyvinylpolypyrrolidone and polyvinylpyrrolidone are mixed, and water is granulated, drying, and by the compacting of 1.2mm screen cloth, and with eccentric pelleter film-making.
At room temperature, the intrinsic bitterness of reactive compound is covered in the 100ml of soluble tablet aqueous suspension to a great extent.
In the American Pharmacopeia blade mixer, measure the release of this active mixture, obtain following result:
Release medium
900ml water 900ml 0.1N HCl
After 5 minutes 32.2% 96.4%
After 15 minutes 47.4% 100%
58.9% 100% embodiment 3 after 30 minutes
With the higher fatty acids of Palmic acid, prepare levofloxacin semihydrate soluble tablet product according to method of the present invention as taste masking:
Levofloxacin semihydrate 512.46mg
Palmic acid 422.00mg
Microcrystalline Cellulose 457.54mg
Polyvinylpolypyrrolidone 150.00mg
Rasp berry correctives 30.00mg
Glucide 60.00mg
Handle levofloxacin semihydrate and Palmic acid according to the method that embodiment 1 describes, obtain the concealed basic mixture of taste.
Said mixture is mixed with microcrystalline Cellulose, polyvinylpolypyrrolidone, rasp berry correctives and glucide, with the total mixture compacting and by 1.0mm screen cloth dry granulation.This is made soluble tablet in granule.
In the American Pharmacopeia blade mixer, measure the release of this active mixture, obtain following result:
Release medium
900ml water 900ml 0.1N HCl
After 5 minutes 43.5% 100%
After 15 minutes 58.9% 100%
73.9% 100% embodiment 4 after 30 minutes
The higher fatty acids of making taste masking with stearic acid according to method of the present invention prepare the Flucloxacillin soluble tablet.Flucloxacillin be the example of the dissolubility medicine lower than levofloxacin.
Flucloxacillin 500.00mg
Stearic acid 600.00mg
Corn starch 711.46mg
Microcrystalline Cellulose 638.32mg
Polyvinylpolypyrrolidone 146.22mg
Polymolecularity silicon 14.00mg
Pears odor type correctives 30.00mg
Glucide 40.00mg acetoacetate derivative (Acesulfam K) 20.00mg
With method similar to Example 1 handle Flucloxacillin and stearic acid, obtain the concealed basic mixture of taste.Corn starch, microcrystalline Cellulose, polyvinylpolypyrrolidone, polymolecularity Silicon stone, pears odor type correctives, glucide and acetoacetate derivative are mixed with basic mixture.With eccentric pelleter with the total mixture film-making.
In the American Pharmacopeia blade mixer, measure the release of this active mixture, obtain following result:
Release medium
900ml water 900ml 0.1N HCl
After 5 minutes 7.6% 94.9%
After 15 minutes 16.5% 99.5%
24% 100% embodiment 5 after 30 minutes
According to method of the present invention, the higher fatty acids of making taste masking with stearic acid prepares the ofloxacin soluble tablet.
Ofloxacin 500.00mg
Stearic acid 600.00mg
Corn starch 711.46mg
Microcrystalline Cellulose 638.32mg
Polyvinylpolypyrrolidone 146.22mg
Polymolecularity Silicon stone 14.00mg
Pears correctives 30.00mg
Glucide 40.00mg
Acetoacetate derivative 20.00mg
Handle ofloxacin and stearic acid with method similar to Example 1, obtain the concealed basic mixture of taste.Corn starch, microcrystalline Cellulose, polyvinylpolypyrrolidone, polymolecularity Silicon stone, pears correctives, glucide and acetoacetate derivative are mixed with basic mixture, with the total mixture compacting, granulate and with eccentric pelleter film-making by the 1.0mm screen cloth.
In the American Pharmacopeia blade mixer, measure the release of this active mixture, obtain following result:
Release medium
900ml water 900ml 0.1N HCl
After 5 minutes 6.8% 87.3%
After 15 minutes 14.4% 100%
20.6% 100% embodiment 6,7,8 and 9 after 30 minutes
Make the taste masking agent with different waxy substances, the soluble tablet of preparation levofloxacin semihydrate.
Embodiment 9 10 11 12 levofloxacin semihydrate 512.45mg 512.45mg 512.45mg 512.45mg
Stearic acid 422.00mg---
Stearyl alcohol-422.00mg--
Castor oil hydrogenated--422.00mg-glyceryl monostearate---422.00mg polyvinylpyrrolidone 25000 10.00mg 10.00mg 10.00mg 10.00mg
Corn starch 487.55mg 487.55mg 487.55mg 487.55mg
Microcrystalline Cellulose 400.00mg 400.00mg 400.00mg 400.00mg micronize polyvinylpolypyrrolidone 100.00mg 100.00mg 100.00mg 100.00mg
In mortar, grind levofloxacin semihydrate and stearic acid or stearyl alcohol or castor oil hydrogenated or glyceryl monostearate, and in drying oven, heated 1 hour at 80 ℃.With the cooling of this mixture, to pulverize and mix with polyvinylpyrrolidone 25000, corn starch, microcrystalline Cellulose and micronized polyvinylpolypyrrolidone, water is with this granulating mixture, and drying is pressed into tablet by the 1mm screen cloth and with this granule.
In the American Pharmacopeia blade mixer, measure the release of this active mixture, obtain following result: embodiment 9 10 11 12
Release medium water is after 5 minutes after 33.5% 64.3% 51.9% 61.6% 15 minutes after 46.4% 81.7% 76.1% 74.4% 30 minutes 63.4% 90.6% 89.3% 81.5%
Release medium 0.1N HCl is after 5 minutes after 95.3% 91.6% 81.2% 85.1% 15 minutes after 100% 99.4% 94.0% 93.8% 30 minutes 100% 100% 100% 98.6%
Be suspended in the soluble tablet of embodiment 9 to 12 in 100 water respectively and estimate taste, have only the taste of the soluble tablet of embodiment 9 to obtain covering aptly.The comparative example 1
Make higher fatty acids with Palmic acid, prepared levofloxacin semihydrate soluble tablet without the inventive method.Levofloxacin semihydrate 512.46mg Palmic acid 422.00mg microcrystalline Cellulose 807.54mg polyvinylpolypyrrolidone 150.00mg rasp berry correctives 30.00mg glucide 60.00mg
Levofloxacin semihydrate, Palmic acid, microcrystalline Cellulose, polyvinylpolypyrrolidone, rasp berry correctives and glucide are mixed, and compacting is also passed through 1.0mm screen cloth dry granulation.This dried granule is made soluble tablet.
In the American Pharmacopeia blade mixer, measure the release of this active mixture, obtain following result:
Release medium
900ml water 900ml 0.1N HCl
After 5 minutes 89.9% 98%
After 15 minutes 100% 100%
After 30 minutes 100% 100%
Compare with the soluble tablet of embodiment 3, be suspended in this soluble tablet in the 100ml water after, the intrinsic bitterness of the medicine of feeling is much better than.The comparative example 2
Need not method of the present invention, also without higher fatty acids, prepared the Flucloxacillin soluble tablet.
Flucloxacillin 500.00mg
Corn starch 711.46mg
Microcrystalline Cellulose 638.32mg
Polyvinylpolypyrrolidone 146.22mg
Polymolecularity Silicon stone 14.00mg
Pears odor type correctives 30.00mg
Glucide 40.00mg
Acetoacetate derivative 20.00mg
Will Flucloxacillin, corn starch, microcrystalline Cellulose, polyvinylpolypyrrolidone, polymolecularity Silicon stone, pears odor type correctives, glucide and acetoacetate derivative mix and be pressed into tablet.
In the American Pharmacopeia blade mixer, measure the release of this active mixture, obtain following result:
Release medium
900ml water 900ml 0.1N HCl
After 5 minutes 40.1% 98.2%
After 15 minutes 62.2% 100%
After 30 minutes 73.2% 100%
After being suspended in embodiment 4 and comparative example's 2 soluble tablet in the 100ml water respectively, the taste result of the test of following shows: the preparation of the embodiment 4 that the taste of reactive compound is covered according to method of the present invention does not have bitterness; And not according to method of the present invention, but be determined very significantly according to the inherent bitterness of chemical compound in the preparation of comparative example's 2 preparations.The comparative example 3
Not according to method of the present invention, also prepare the ofloxacin soluble tablet without higher fatty acids.
Ofloxacin 500.00mg
Corn starch 711.46mg
Microcrystalline Cellulose 638.32mg
Polyvinylpolypyrrolidone 146.22mg
Polymolecularity Silicon stone 14.00mg
Pears odor type correctives 30.00mg
Glucide 40.00mg
Acetoacetate derivative 20.00mg
Ofloxacin, corn starch, microcrystalline Cellulose, polyvinylpolypyrrolidone, polymolecularity Silicon stone, pears odor type correctives, glucide and acetoacetate derivative mixed and be pressed into tablet.
In the American Pharmacopeia blade mixer, measure the release of this active mixture, obtain following result:
Release medium
900ml water 900ml 0.1N HCl
After 5 minutes 89.9% 95.4%
After 15 minutes 100% 97.4%
After 30 minutes 100% 100%
After being suspended in embodiment 5 and comparative example's 3 soluble tablet in the 100ml water respectively, the taste result of the test of following shows: the preparation of the embodiment 5 that the taste of reactive compound is covered according to method of the present invention does not have bitterness; And not according to method of the present invention, but be determined very significantly according to the inherent bitterness of chemical compound in the preparation of comparative example's 3 preparations.
Claims (13)
1. the method for an oral drug preparation quinolone derivative for preparing antibacterial activity, concealed, the reactive compound rapid release of taste, comprising, quinolone derivative is mixed with at least a higher fatty acids, and, temperature is increased to 30 ℃ to 140 ℃ by the while or with post-heating.
2. the described method of claim 1, wherein temperature is 40 ℃ to 120 ℃.
3. claim 1 or 2 described methods, wherein temperature is 65 ℃ to 85 ℃.
4. one or more described methods in the claim 1 to 3, wherein the hot blender with high revolution comes heating blends.
5. one or more described methods in the claim 1 to 4 wherein only elevate the temperature by frictional heat in blender.
6. one or more described methods in the claim 1 to 5, wherein the weight ratio of one or more quinolone derivatives and one or more fatty acids is 1: 0.3 to 1: 4.
7. one or more described methods in the claim 1 to 6, wherein fatty acid contains 10 carbon atoms at least.
8. one or more described methods in the claim 1 to 7, wherein fatty acid contains 10 to 18 carbon atoms.
9. one or more described methods in the claim 1 to 8, wherein the quinolone derivative of used antibacterial activity be quinolone derivative such as levofloxacin, ofloxacin, ciprofloxacin, Flucloxacillin, west cough up husky star or enoxacin.
10. one or more described methods in the claim 1 to 9, wherein the quinolone derivative of antibacterial activity is levofloxacin or ofloxacin.
11. one or more described methods in the claim 1 to 10, wherein the quinolone derivative of antibacterial activity and the mixture of higher fatty acids are reached, in case of necessity, other additive is processed, obtain reactive compound, taste needs concealed pharmaceutical dosage form, as soluble tablet, chewable tablet, sachet etc.
12. can be according to the preparation of the described method preparation of claim 1 to 11.
13. be used to prepare the medicine for the treatment of bacterial infection, by the described preparation of claim 12.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98104286A CN1188646A (en) | 1997-01-24 | 1998-01-22 | Preparation of concealed taste preparations of antibucterially active quinlone derivatives |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19702443.2 | 1997-01-24 | ||
| CN98104286A CN1188646A (en) | 1997-01-24 | 1998-01-22 | Preparation of concealed taste preparations of antibucterially active quinlone derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1188646A true CN1188646A (en) | 1998-07-29 |
Family
ID=5218218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN98104286A Pending CN1188646A (en) | 1997-01-24 | 1998-01-22 | Preparation of concealed taste preparations of antibucterially active quinlone derivatives |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1188646A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103673451A (en) * | 2012-09-22 | 2014-03-26 | 博西华家用电器有限公司 | Refrigeration tool |
| CN105451771A (en) * | 2013-03-15 | 2016-03-30 | 阿根塔制造有限公司 | Chewable formulation |
| CN111529499A (en) * | 2020-06-11 | 2020-08-14 | 华中农业大学 | Enrofloxacin flavored tablets for livestock and preparation method thereof |
-
1998
- 1998-01-22 CN CN98104286A patent/CN1188646A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103673451A (en) * | 2012-09-22 | 2014-03-26 | 博西华家用电器有限公司 | Refrigeration tool |
| CN105451771A (en) * | 2013-03-15 | 2016-03-30 | 阿根塔制造有限公司 | Chewable formulation |
| CN105451771B (en) * | 2013-03-15 | 2020-05-19 | 阿根塔创新有限公司 | Chewable formulation |
| CN111529499A (en) * | 2020-06-11 | 2020-08-14 | 华中农业大学 | Enrofloxacin flavored tablets for livestock and preparation method thereof |
| CN111529499B (en) * | 2020-06-11 | 2021-09-17 | 华中农业大学 | Enrofloxacin flavored tablets for livestock and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1136853C (en) | Tablets containing 'beta'-lactam antibiotic and process for producing the same | |
| CN1146410C (en) | Controlled release formulation | |
| CN1298317C (en) | Tamsulosin tablets | |
| CN1056277C (en) | Pharmaceutical formulations | |
| CN1220485C (en) | Method for making granules with masked taste and instant release of active particle | |
| CN1239151C (en) | Tablets quickly disintegrating in oral cavity | |
| CN1691965A (en) | Pharmaceutical composition for controlled release and manufacturing method thereof | |
| CN1642546A (en) | Solid preparation containing single crystal form | |
| CN1423559A (en) | Controlled-release compositions containing opioid agonist and antagonist | |
| CN1124452A (en) | Process | |
| CN1247188C (en) | Medicinal composition | |
| CN1913876A (en) | Drug-containing grains and solid preparation containing the grains | |
| CN1109328A (en) | Sustained release formulations for 24 hour release of metoprolol | |
| CN1309570A (en) | Excipient | |
| CN1823091A (en) | Functional starch powder | |
| CN1747723A (en) | Composition comprising a mixture of active principles, and method of preparation | |
| CN1479611A (en) | Pharmaceutical paste comprising acid-labile activeingredient | |
| CN1206986C (en) | Coated trimebutine maleate tablet | |
| CN1469737A (en) | Medicinal compositions quickly disintegrating in the oral cavity and process for producing the same | |
| CN1883456A (en) | Flavor-hidden pharmaceutical granule, preparation method and use thereof | |
| CN1762357A (en) | Oral medicinal formulation of moxifloxacin and its preparation method | |
| CN1309375C (en) | Granulating process of medicinal material and supplementary material for dispensing directly | |
| CN1330546A (en) | Compositions comprising cefuroxime axetil | |
| CN1400896A (en) | Ibuprofen containing active agent preparation | |
| JPH10203985A (en) | Production of taste-masking agent of antibacterial quinolone derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1010080 Country of ref document: HK |